News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
485,654 Results
Type
Article (8036)
Company Profile (140)
Press Release (477573)
Multimedia
Podcasts (4)
Webinars (6)
Section
Business (166745)
Career Advice (305)
Deals (25738)
Drug Delivery (7)
Drug Development (52876)
Employer Resources (14)
FDA (9760)
Job Trends (8574)
News (238191)
Policy (17906)
Tag
2027 Bio NC Standard (1)
2027 Biotech Bay Elite (3)
2027 Biotech Bay Standard (6)
2027 Biotech Beach Elite (1)
2027 Genetown Elite (1)
2027 Genetown Standard (2)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (1)
Academia (488)
Accelerated approval (26)
ADA (18)
Adcomms (1)
Allergies (97)
Alliances (33154)
ALS (106)
Alzheimer's disease (984)
Antibody-drug conjugate (ADC) (276)
Approvals (10396)
Artificial intelligence (326)
ASCO (159)
Autoimmune disease (216)
Automation (29)
Bankruptcy (263)
Best Places to Work (6958)
BIO (36)
Biologics (9)
BIOSECURE Act (1)
Biosimilars (114)
BioSpace Insights (17)
Biotechnology (88)
Bladder cancer (139)
Brain cancer (30)
Breast cancer (516)
Cancer (3717)
Cardiovascular disease (225)
Career advice (245)
Career pathing (1)
CAR-T (177)
CDMO (10)
Celiac Disease (1)
Cell therapy (483)
Cervical cancer (35)
Clinical research (47985)
Collaboration (1270)
Commercialization (3)
Compensation (1518)
Complete response letters (34)
COVID-19 (758)
CRISPR (64)
C-suite (787)
Cystic fibrosis (86)
Data (5805)
Denatured (4)
Depression (103)
Dermatology (67)
Diabetes (350)
Diagnostics (4202)
Digital health (39)
Diversity (1)
Diversity, equity & inclusion (4)
Drug discovery (158)
Drug pricing (7)
Drug shortages (2)
Duchenne muscular dystrophy (166)
Earnings (73741)
Editorial (1)
Employer branding (2)
Employer resources (14)
Events (88031)
Executive appointments (709)
FDA (12447)
Fibrodysplasia Ossificans Progressiva (9)
Friedreich's ataxia (18)
Frontotemporal dementia (24)
Funding (937)
Gene editing (126)
Generative AI (9)
Gene therapy (329)
GLP-1 (294)
Government (946)
Grass and pollen (2)
Guidances (281)
Healthcare (9367)
Hematology (94)
HIV (53)
Huntington's disease (22)
IgA nephropathy (65)
Immunology and inflammation (101)
Immuno-oncology (61)
Indications (159)
Infectious disease (948)
Inflammatory bowel disease (127)
Inflation Reduction Act (4)
Influenza (84)
Intellectual property (259)
Interviews (41)
IPO (12387)
IRA (2)
Job creations (1968)
Job search strategy (235)
JPM (1)
Kidney cancer (16)
Layoffs (59)
Legal (5195)
Licensing (16)
Liver cancer (45)
Longevity (19)
Lung cancer (520)
Lymphoma (257)
Machine learning (27)
Management (3)
Manufacturing (551)
Marketing (8)
MASH (118)
Medical affairs (2)
Medical device (8672)
Medtech (8826)
Mergers & acquisitions (14400)
Metabolic disorders (718)
mRNA (60)
Multiple sclerosis (105)
NASH (4)
Neurodegenerative disease (224)
Neuropsychiatric disorders (40)
Neuroscience (1851)
NextGen: Class of 2026 (3150)
Non-profit (843)
Obesity (227)
Opinion (10)
Ovarian cancer (161)
Pain (176)
Pancreatic cancer (204)
Parkinson's disease (204)
Partnered (12)
Patents (490)
Patient recruitment (523)
Peanut (31)
People (41315)
Peptides (1)
Pharmaceutical (30)
Pharmacy benefit managers (9)
Phase 1 (15501)
Phase 2 (21422)
Phase 3 (14449)
Pipeline (7597)
Policy (18)
Postmarket research (1570)
Preclinical (6550)
Press Release (34)
Prostate cancer (193)
Psychedelics (7)
Radiopharmaceuticals (194)
Rare diseases (583)
Real estate (3022)
Recruiting (6)
Regulatory (14900)
Reports (23)
Research institute (584)
Resumes & cover letters (45)
Rett syndrome (42)
RNA editing (5)
RSV (48)
Schizophrenia (102)
Series A (158)
Series B (122)
Service/supplier (5)
Sickle cell disease (63)
Spinal muscular atrophy (89)
Sponsored (5)
Startups (2019)
Stomach cancer (3)
Supply chain (51)
Vaccines (332)
Venture capital (17)
Weight loss (74)
Women's health (83)
Date
Today (79)
Last 7 days (347)
Last 30 days (1487)
Last 365 days (19050)
2026 (13293)
2025 (19251)
2024 (22986)
2023 (26538)
2022 (34586)
2021 (37167)
2020 (33468)
2019 (23256)
2018 (17468)
2017 (18765)
2016 (17917)
2015 (24268)
2014 (21679)
2013 (18138)
2012 (20222)
2011 (20441)
2010 (20332)
Location
Africa (228)
Alabama (75)
Alaska (2)
Arizona (308)
Arkansas (11)
Asia (17936)
Australia (2106)
California (12261)
Canada (3212)
China (538)
Colorado (490)
Connecticut (423)
Delaware (210)
Europe (24674)
Florida (1839)
Georgia (390)
Hawaii (3)
Idaho (46)
Illinois (718)
India (52)
Indiana (320)
Iowa (16)
Japan (415)
Kansas (101)
Kentucky (31)
Louisiana (27)
Maine (26)
Maryland (1221)
Massachusetts (8047)
Michigan (311)
Minnesota (568)
Mississippi (4)
Missouri (82)
Montana (20)
Nebraska (11)
Nevada (119)
New Hampshire (60)
New Jersey (2673)
New Mexico (12)
New York (2875)
North Carolina (1310)
North Dakota (4)
Northern California (6161)
Ohio (287)
Oklahoma (14)
Oregon (16)
Pennsylvania (2288)
Puerto Rico (20)
Rhode Island (30)
South America (406)
South Carolina (77)
South Dakota (1)
Southern California (5101)
Tennessee (122)
Texas (1989)
United States (39737)
Utah (367)
Vermont (1)
Virginia (156)
Washington D.C. (38)
Washington State (953)
West Virginia (1)
Wisconsin (74)
Wyoming (1)
485,654 Results for "lensgen inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Biotech Beach
LensGen® Receives IDE Approval from the U.S. FDA to Begin Clinical Study of the Juvene® Presbyopia-Correcting Intraocular Lens
LensGen, Inc. announced today that it has received approval for an Investigational Device Exemption (IDE) from the U.S. Food and Drug Administration (FDA) to initiate a pivotal study of the company’s Juvene intraocular lens (IOL) for patients with cataracts.
November 29, 2021
·
3 min read
Deals
LensGen® Closes $10 Million Financing and Welcomes James V. Mazzo to its Board of Directors
LensGen, Inc., an ophthalmic medical device company and developer of Juvene®, a disruptive fluid-optic intraocular lens for cataract and presbyopia treatment, announces the initial Closing of a $10 million of the $20 million Bridge Financing.
August 20, 2020
·
4 min read
Biotech Beach
LensGen® Announces Presentations and Scientific Papers on Juvene™ in Paris
LensGen®, Inc. will be featured in several activities as the European Society for Cataract and Refractive Surgery (ESCRS) event in Paris, France begins.
September 10, 2019
·
3 min read
Biotech Beach
LensGen® to Review Latest Juvene™ IOL Results At AAO
LensGen®, Inc. will review its latest data for the world’s first modular fluid optic Intraocular Lens (IOL) in several activities around the American Academy of Ophthalmology (AAO) annual meeting in San Francisco this week.
October 8, 2019
·
3 min read
Press Releases
Tevogen Bio Holdings Inc. Becomes Tevogen Inc.
July 29, 2026
·
4 min read
Policy
LensGen Announces Funding And Patent Success
LensGen®, Inc. is reporting significant progress in its effort to transform how presbyopia is addressed.
July 17, 2018
·
2 min read
Press Releases
Carlsmed, Inc. Announces Chief Operating Officer Appointment
September 8, 2026
·
2 min read
Press Releases
Glucotrack, Inc. Announces Reverse Stock Split
August 27, 2026
·
6 min read
Press Releases
PostEra’s Fertility programs acquired by EMD Serono, Inc.
September 9, 2026
·
2 min read
Press Releases
argenx Completes Acquisition of Forte Biosciences, Inc.
August 27, 2026
·
6 min read
1 of 48,566
Next
